An Alzheimer's drug developed by Swiss company Roche could not be proven in clinical trials to slow the progression of dementia, the pharmaceutical giant said Monday.
In a statement, Roche said the drug, gantenerumab, "did not meet their primary endpoint of slowing clinical decline" in a pair of studies conducted by the company. The identical studies, which were conducted with patients over the course of two years, were held in an effort to prove that gantenerumab could preserve certain functions in early Alzheimer's patients, including problem-solving skills, memory, and judgment.
While the trials were successful in showing a slight rate of decline, neither of them were described by Roche as being "statistically significant."
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"So many of our families have been directly affected by Alzheimer's, so this news is very disappointing to deliver," said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and head of global product development. "We are profoundly grateful to the study participants, their care partners, and study sites for their contributions to this research."
The faults of the studies now leave a trio of Roche's competitors, Biogen, Eisai, and Eli Lilly as the leaders in the medical community's effort to get an Alzheimer's treatment on the market.
The results saw economic ramifications as well, and Reuters reported that financial services firm Credit Suisse called the studies an "unequivocal" failure. Shares of Roche fell to their lowest in seven weeks, Reuters noted, with shares of Biogen and Eli Lilly rising 3.8 percent and 2.3 percent, respectively.
-
5 artfully drawn cartoons about Donald Trump's Epstein doodleCartoons Artists take on a mountainous legacy, creepy art, and more
-
Violent videos of Charlie Kirk’s death are renewing debate over online censorshipTalking Points Social media ‘promises unfiltered access, but without guarantees of truth and without protection from harm’
-
What led to Poland invoking NATO’s Article 4 and where could it lead?TODAY'S BIG QUESTION After a Russian drone blitz, Warsaw’s rare move to invoke the important NATO statute has potentially moved Europe closer to continent-wide warfare
-
Scientists are speeding up evolutionUnder the radar Proteins can evolve in minutes
-
A new subtype of diabetes was found and it may require different treatmentUnder the radar It is prevalent in Black Africans and Americans
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Why the FDA wants to restrict kratom-related productsIn the Spotlight The compound is currently sold across the United States
-
Scientists are developing artificial blood for use in emergenciesUnder the radar It could aid in global blood shortages
-
Babies born using 3 people's DNA lack hereditary diseaseUnder the Radar The method could eliminate mutations for future generations
-
Measles cases surge to 33-year highSpeed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
